<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medecol</journal-id><journal-title-group><journal-title xml:lang="ru">Медицина и экология</journal-title><trans-title-group xml:lang="en"><trans-title>Medicine and ecology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-6045</issn><issn pub-type="epub">2305-6053</issn><publisher><publisher-name>Карагандинский медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medecol-101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>АССОЦИАЦИЯ «ТРАДИЦИОННЫХ» ФАКТОРОВ РИСКА И УРОВНЯ ХЕМОКИНА CXCL16 В РАЗВИТИИ КАРДИОВАСКУЛЯРНЫХ событий</article-title><trans-title-group xml:lang="en"><trans-title>ASSOCIATION OF «TRADITIONAL» RISK FACTORS AND CHEMOCIN CXCL16 LEVEL IN THE DEVELOPMENT OF CARDIOVASCULAR EVENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Байдильдина</surname><given-names>Б. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Baidildina</surname><given-names>B. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тургунова</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Turgunova</surname><given-names>L. G.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бачева</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bacheva</surname><given-names>I. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахмалтдинова</surname><given-names>Л. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmaltdinova</surname><given-names>L. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларюшина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Laryushina</surname><given-names>Ye. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Медицинский университет Караганды<country>Казахстан</country></aff><aff xml:lang="en">Karaganda medical university<country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>07</day><month>09</month><year>2021</year></pub-date><volume>0</volume><issue>1</issue><fpage>92</fpage><lpage>98</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Байдильдина Б.Н., Тургунова Л.Г., Бачева И.В., Ахмалтдинова Л.Л., Ларюшина Е.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Байдильдина Б.Н., Тургунова Л.Г., Бачева И.В., Ахмалтдинова Л.Л., Ларюшина Е.М.</copyright-holder><copyright-holder xml:lang="en">Baidildina B.N., Turgunova L.G., Bacheva I.V., Akhmaltdinova L.L., Laryushina Y.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medecol.qmu.kz/jour/article/view/101">https://medecol.qmu.kz/jour/article/view/101</self-uri><abstract><p>Цель работы - оценка влияния факторов кардиоваскулярного риска и уровня хемокина CXCL16 на развитие сердечно-сосудистых событий. Материалы и методы. Проанализированы результаты наблюдения 223 лиц в возрасте от 25 до 65 лет (177 женщин, 46 мужчин) с мая 2014 по декабрь 2018 г. Исследование включало в себя социальнодемографические, антропометрические данные, измерение артериального давления, исследование холестерина, глюкозы, хемокина CXCL16. За кардиоваскулярное событие принимали развитие острого нарушения мозгового кровообращения, острого коронарного синдрома, транзиторной ишемической атаки, впервые диагносцированной стенокардии. Анализ данных осуществляли с помощью пакета статистических программ SPSS 22. Результаты и обсуждение. Частота кардиоваскулярных событий составила 15,7%. Выявлены различия между группами в зависимости от возраста (р=0,002), уровня систолического АД (р=0,029), объема талии (р=0,003), степени риска по шкале SCORE и уровня хемокина CXCL 16 (р=0,009). Заключение. Обнаружена взаимосвязь между шкалой SCORE, уровнем хемокина CXCL16 и развитием сердечно-сосудистых событий. Выводы. Необходимы дальнейшие исследования по изучению прогностической оценки биомаркеров.</p></abstract><trans-abstract xml:lang="en"><p>Material and methods. We analyzed the results of the observation of 223 persons aged 25 to 65 years (177 women, 46 men) from May 2014 to December 2018. The study included socio-demographic, anthropometric data, blood pressure measurement, the study of cholesterol, glucose, chemokine CXCL16. For the cardiovascular event took the development of acute cerebrovascular accident, acute coronary syndrome, transient ischemic attack, first diagnosed angina. Data analysis was performed using the SPSS 22 statistical software package. Results and discussion. The frequency of cardiovascular events was 15.7%. Differences were found between groups depending on age (p=0.002), systolic blood pressure level (p=0.029), waist size (p=0.003), risk degree on a SCORE scale (р=0,002), and CXCL16 chemokine level (p=0.009). Conclusion. The relationship between the SCORE scale, the CXCL 16 chemokine level and the development of cardiovascular events has been found. Findings. Further research is needed on the prognostic evaluation of biomarkers.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>шкала SCORE</kwd><kwd>кардиоваскулярные события</kwd><kwd>хемокин CXCL16</kwd><kwd>кардиоваскулярлы асқыныс</kwd><kwd>хемокин CXCL16</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SCORE scale</kwd><kwd>cardiovascular events</kwd><kwd>chemokine CXCL16</kwd><kwd>SCORE шкаласы</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Искаков Е. Б. Эпидемиология сердечно-сосудистых заболеваний //Медицина и экология. - 2017. - №1. - С. 19-28.</mixed-citation><mixed-citation xml:lang="en">Искаков Е. Б. Эпидемиология сердечно-сосудистых заболеваний //Медицина и экология. - 2017. - №1. - С. 19-28.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кочергина А. М. Гендерные различия факторов кардиоваскулярного риска у пациентов разных возрастных групп (по данным исследования ЭССЕ-РФ) /А. М. Кочергина, В. Н. Каретникова, О. Л. Барбарам //Медицина в Кузбасе. - 2015. - №1. - С. 1-8.</mixed-citation><mixed-citation xml:lang="en">Кочергина А. М. Гендерные различия факторов кардиоваскулярного риска у пациентов разных возрастных групп (по данным исследования ЭССЕ-РФ) /А. М. Кочергина, В. Н. Каретникова, О. Л. Барбарам //Медицина в Кузбасе. - 2015. - №1. - С. 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ МЗ РК № 669 от 31 августа 2017 года «О внесении изменения в Приказ Министра здравоохранения Республики Казахстан от 9 сентября 2010 года №704 «Об утверждении Правил организации скрининга»</mixed-citation><mixed-citation xml:lang="en">Приказ МЗ РК № 669 от 31 августа 2017 года «О внесении изменения в Приказ Министра здравоохранения Республики Казахстан от 9 сентября 2010 года №704 «Об утверждении Правил организации скрининга»</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Degano I. The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index /i. R. Degano, J. Marrugat, M. Grau // Scientific Reports. - 2017. - №7 (1). - P. 1-8.</mixed-citation><mixed-citation xml:lang="en">Degano I. The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index /i. R. Degano, J. Marrugat, M. Grau // Scientific Reports. - 2017. - №7 (1). - P. 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dhingra R. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework /R. Dhingra, R. Vasan //Clinical and pharmacological therapy. - 2001. - V. 69. - P. 89 -95.</mixed-citation><mixed-citation xml:lang="en">Dhingra R. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework /R. Dhingra, R. Vasan //Clinical and pharmacological therapy. - 2001. - V. 69. - P. 89 -95.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dhingra R. Biomarkers in Cardiovascular Disease. Statistical Assessment and Section on Key Novel Heart Failure Biomarkers /R. Dhingra, R. Vasan //Trends Cardiovascular Medicine. -2017. - V. 27(2). - P. 123-133.</mixed-citation><mixed-citation xml:lang="en">Dhingra R. Biomarkers in Cardiovascular Disease. Statistical Assessment and Section on Key Novel Heart Failure Biomarkers /R. Dhingra, R. Vasan //Trends Cardiovascular Medicine. -2017. - V. 27(2). - P. 123-133.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fan H. Abdominal obesity is strongly associated with cardiovascular disease and its risk factors in elderly and very elderly communitydwelling Chinese /H. Fan, X. Zheng, X. Chen // Sci. Rep. - 2016. - V. 6: 21521.</mixed-citation><mixed-citation xml:lang="en">Fan H. Abdominal obesity is strongly associated with cardiovascular disease and its risk factors in elderly and very elderly communitydwelling Chinese /H. Fan, X. Zheng, X. Chen // Sci. Rep. - 2016. - V. 6: 21521.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Galiuto L. Gender differences in cardiovascular disease /L. Galiuto, G. Locorotondo // Journal of Integrative Cardiology. - 2015. - V. 1 (1). - P. 20-22.</mixed-citation><mixed-citation xml:lang="en">Galiuto L. Gender differences in cardiovascular disease /L. Galiuto, G. Locorotondo // Journal of Integrative Cardiology. - 2015. - V. 1 (1). - P. 20-22.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y. Biomarkers of cardiovascular disease /Y. Huang, K. Gulshan, T. Nguyen, Y. Wu //Disease Markers. - 2017. - V. 24. - P. 1-2.</mixed-citation><mixed-citation xml:lang="en">Huang Y. Biomarkers of cardiovascular disease /Y. Huang, K. Gulshan, T. Nguyen, Y. Wu //Disease Markers. - 2017. - V. 24. - P. 1-2.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Laugsand L. E. Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway /l. E. Laugsand, B. O. Asvold, L. J. Vatten // Atherosclerosis. - 2016. - V. 244. - P. 188-194.</mixed-citation><mixed-citation xml:lang="en">Laugsand L. E. Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway /l. E. Laugsand, B. O. Asvold, L. J. Vatten // Atherosclerosis. - 2016. - V. 244. - P. 188-194.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lehrke M. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans /M. Lehrke, S. C. Millington, M. Lefterova //J. Am. Coll. Cardiol. - 2007. - V. 49 (4). - P. 442-449.</mixed-citation><mixed-citation xml:lang="en">Lehrke M. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans /M. Lehrke, S. C. Millington, M. Lefterova //J. Am. Coll. Cardiol. - 2007. - V. 49 (4). - P. 442-449.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">National Center for Health Statistics (NCHS) and the National Heart, Lung, and Blood Institute (NHLBI), Women and Cardiovascular Diseases - Statistics, 2009.</mixed-citation><mixed-citation xml:lang="en">National Center for Health Statistics (NCHS) and the National Heart, Lung, and Blood Institute (NHLBI), Women and Cardiovascular Diseases - Statistics, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Nazari A. Cardiovascular Disease in Iranian Hemodialysis Patients /A. Nazari, A. M. Sardoo, E. T. Fard //biomedical and pharmacology journal. - 2017. - V. 10 (1). - P. 1-7.</mixed-citation><mixed-citation xml:lang="en">Nazari A. Cardiovascular Disease in Iranian Hemodialysis Patients /A. Nazari, A. M. Sardoo, E. T. Fard //biomedical and pharmacology journal. - 2017. - V. 10 (1). - P. 1-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Oguoma V. M. Prevalence of cardiovascular disease risk factors among a Nigerian adult population: relationship with income level and accessibility to CVD risks screening /V. M. Oguoma, E. U. Nwose, T. C. Skinner //BMC Public Health. - 2015. - V. 15. - P. 397.</mixed-citation><mixed-citation xml:lang="en">Oguoma V. M. Prevalence of cardiovascular disease risk factors among a Nigerian adult population: relationship with income level and accessibility to CVD risks screening /V. M. Oguoma, E. U. Nwose, T. C. Skinner //BMC Public Health. - 2015. - V. 15. - P. 397.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Piepoli M. F. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The 6th Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR) /M. F. Piepoli, A. W. Hoes, S. Agewall // European Heart Journal. - 2016. - V. 37 (29). - P. 2315-2381.</mixed-citation><mixed-citation xml:lang="en">Piepoli M. F. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The 6th Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR) /M. F. Piepoli, A. W. Hoes, S. Agewall // European Heart Journal. - 2016. - V. 37 (29). - P. 2315-2381.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shields M. Abdominal obesity and cardiovascular disease risk factors within body mass index categories /M. Shields, M. S. Tremblay, S. Connor Gorber //Health Rep. - 2012. - V. 23 (2). - P. 7-15.</mixed-citation><mixed-citation xml:lang="en">Shields M. Abdominal obesity and cardiovascular disease risk factors within body mass index categories /M. Shields, M. S. Tremblay, S. Connor Gorber //Health Rep. - 2012. - V. 23 (2). - P. 7-15.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Simon-Tuval T. The association between adherence to cardiovascular medications and healthcare utilization /T. Simon-Tuval, N. Triki, G. Chodick //The European Journal of Health Economics. - 2008. - V. 17 (5). - P. 603-610.</mixed-citation><mixed-citation xml:lang="en">Simon-Tuval T. The association between adherence to cardiovascular medications and healthcare utilization /T. Simon-Tuval, N. Triki, G. Chodick //The European Journal of Health Economics. - 2008. - V. 17 (5). - P. 603-610.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas L. Lower Education Level Is Associated with Higher Risk for Cardiovascular Disease /L. Thomas, Y. Kubota //NEJM Journal Watch. - 2017. - V. 1 (3). - P. 1-2.</mixed-citation><mixed-citation xml:lang="en">Thomas L. Lower Education Level Is Associated with Higher Risk for Cardiovascular Disease /L. Thomas, Y. Kubota //NEJM Journal Watch. - 2017. - V. 1 (3). - P. 1-2.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tohoku J. CXC chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: a 2-year follow-up study //Experimental Medicine. - 2011. - V. 223 (4). - P. 277-283.</mixed-citation><mixed-citation xml:lang="en">Tohoku J. CXC chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: a 2-year follow-up study //Experimental Medicine. - 2011. - V. 223 (4). - P. 277-283.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J. Novel biomarkers for cardiovascular risk prediction /J. Wang, G. J. Tan, L. N. Han //Journal of Geriatric Cardiology. - 2017. -V.14(2). - P. 135-150.</mixed-citation><mixed-citation xml:lang="en">Wang J. Novel biomarkers for cardiovascular risk prediction /J. Wang, G. J. Tan, L. N. Han //Journal of Geriatric Cardiology. - 2017. -V.14(2). - P. 135-150.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wong C. W. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis /C. W. Wong, C. S. Kwok, A. Narain //Heart. - 2018. - V. 104 (23). - P. 19371948.</mixed-citation><mixed-citation xml:lang="en">Wong C. W. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis /C. W. Wong, C. S. Kwok, A. Narain //Heart. - 2018. - V. 104 (23). - P. 19371948.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
